CA2441535C - Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport - Google Patents

Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport Download PDF

Info

Publication number
CA2441535C
CA2441535C CA002441535A CA2441535A CA2441535C CA 2441535 C CA2441535 C CA 2441535C CA 002441535 A CA002441535 A CA 002441535A CA 2441535 A CA2441535 A CA 2441535A CA 2441535 C CA2441535 C CA 2441535C
Authority
CA
Canada
Prior art keywords
nucleic acid
cell
cells
acid molecule
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002441535A
Other languages
English (en)
Other versions
CA2441535A1 (fr
Inventor
Volker Oberle
Dirk Hoekstra
Jan Drayer
Paul Peter Tak
Gary Dejong
Sandra Louise Vanderbyl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Chromos Molecular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,979 external-priority patent/US7294511B2/en
Priority claimed from US09/815,981 external-priority patent/US6936469B2/en
Priority claimed from US10/086,745 external-priority patent/US20030186390A1/en
Application filed by Chromos Molecular Systems Inc filed Critical Chromos Molecular Systems Inc
Priority to CA002633522A priority Critical patent/CA2633522A1/fr
Publication of CA2441535A1 publication Critical patent/CA2441535A1/fr
Application granted granted Critical
Publication of CA2441535C publication Critical patent/CA2441535C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des techniques d'apport de molécules d'acides nucléiques dans des cellules et des techniques permettant de mesurer l'apport d'acides nucléiques dans ces cellules et l'expression de ces acides nucléiques. Ces techniques sont conçue en vue d'introduire dans des cellules de grosses molécules d'acides nucléiques, y compris des chromosomes artificiels. Ces techniques sont mises en oeuvre <i>in vitro</i> et <i>in vivo</i>.
CA002441535A 2001-03-22 2002-03-22 Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport Expired - Fee Related CA2441535C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002633522A CA2633522A1 (fr) 2001-03-22 2002-03-22 Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/815,979 US7294511B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US09/815,981 2001-03-22
US09/815,981 US6936469B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US09/815,979 2001-03-22
US10/086,745 2002-02-28
US10/086,745 US20030186390A1 (en) 2001-03-22 2002-02-28 Methods for delivering nucleic acid molecules into cells and assessment thereof
PCT/US2002/009262 WO2002076508A1 (fr) 2001-03-22 2002-03-22 Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002633522A Division CA2633522A1 (fr) 2001-03-22 2002-03-22 Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport

Publications (2)

Publication Number Publication Date
CA2441535A1 CA2441535A1 (fr) 2002-10-03
CA2441535C true CA2441535C (fr) 2008-08-26

Family

ID=27375461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002441535A Expired - Fee Related CA2441535C (fr) 2001-03-22 2002-03-22 Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport

Country Status (6)

Country Link
EP (1) EP1383541A4 (fr)
JP (1) JP2004532205A (fr)
CA (1) CA2441535C (fr)
IL (1) IL157703A0 (fr)
NZ (1) NZ527972A (fr)
WO (1) WO2002076508A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294511B2 (en) 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
NZ528003A (en) 2001-05-30 2006-09-29 Chromos Molecular Systems Inc Platform artificial chromosome expression systems (ACes) containing single or multiple site-specific recombination sites
JP4676679B2 (ja) * 2003-04-02 2011-04-27 帝人株式会社 人工軟骨
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
JP5115686B2 (ja) * 2006-04-17 2013-01-09 学校法人慶應義塾 細胞への薬剤導入装置
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
CN109963506B (zh) 2016-11-22 2024-05-07 西达-赛奈医疗中心 一种新型的转染和药物递送装置
CN117357480B (zh) * 2023-12-08 2024-03-29 北京中科利华医药研究院有限公司 无针经皮注射用组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135313A1 (fr) * 1992-06-18 1994-01-06 Theodore Choi Methodes pour l'obtention d'animaux transgeniques, comportant un chromosome artificiel de levure
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
NL1000884C2 (nl) * 1995-07-25 1997-01-28 Univ Groningen Transportvehikels voor macromoleculen.
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
WO1999025385A1 (fr) * 1997-11-17 1999-05-27 Imarx Pharmaceutical Corp. Procede d'accroissement de la synthese d'acides nucleiques au moyen d'ultrasons
CA2353559A1 (fr) * 1998-12-04 2000-06-15 Genetronics, Inc. Procedes mettant en oeuvre une technique facs pour introduire des chromosomes individuels dans des cellules

Also Published As

Publication number Publication date
IL157703A0 (en) 2004-03-28
EP1383541A1 (fr) 2004-01-28
CA2441535A1 (fr) 2002-10-03
NZ527972A (en) 2006-04-28
JP2004532205A (ja) 2004-10-21
WO2002076508A1 (fr) 2002-10-03
EP1383541A4 (fr) 2009-11-04
WO2002076508B1 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
US20030003435A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030224522A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030113917A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030059940A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
Greenleaf et al. Artificial cavitation nuclei significantly enhance acoustically induced cell transfection
DzAu et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases.
Wells Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo
DE69232497T2 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
US20010008758A1 (en) Delivery of an agent
CA2441535C (fr) Techniques d&#39;apport de molecules d&#39;acides nucleiques dans des cellules et evaluation de cet apport
Mannell et al. Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles
US20030050271A1 (en) Gene transfer into the kidney
US7396919B1 (en) Charge reversal of polyion complexes
CA2398296A1 (fr) Methode de chargement d&#39;un agent dans un globule rouge
Wang et al. Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants
Kaneda et al. Increased expression of DNA cointroduced with nuclear protein in adult rat liver
JP2002512985A (ja) ポリヌクレオチドを脈管系を介して細胞へ送達する方法
Takahashi et al. Adenovirus-mediated gene therapy to liver grafts: successful gene transfer by donor pretreatment
AU2005225124A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
AU6171000A (en) Method for releasing an agent from a red blood cell
Sandovici et al. Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop
Tomita et al. Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases
Shinmura et al. Catheter-delivered in vivo gene transfer into rat myocardium using the fusigenic liposomal mediated method
CA2633522A1 (fr) Techniques d&#39;apport de molecules d&#39;acides nucleiques dans des cellules et evaluation de cet apport
AU2002306877A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150323